I agree that this site is using cookies. You can find further informations here.
X
Drew, Y
964  results:
Search for persons X
?
1

Prevalence of mutations in common tumour types in Northern ..:

Rae, S. ; Plummer, E. ; Fitzgerald, L....
Journal of Cancer Research and Clinical Oncology.  149 (2023)  18 - p. 16355-16363 , 2023
Link: https://doi.org/10.1007/..
 
?
2

Tisotumab vedotin (TV) in patients with previously treated ..:

Hong, D.S. ; Arkenau, H.T. ; de Bono, J....
Gynecologic Oncology.  154 (2019)  - p. 11-12 , 2019
Link: https://doi.org/10.1016/..
 
?
3

An open-label, phase II basket study of olaparib and durval..:

Drew, Y. ; de Jonge, M. ; Hong, S.H....
Gynecologic Oncology.  149 (2018)  - p. 246-247 , 2018
Link: https://doi.org/10.1016/..
 
?
4

The role of PARP in DNA repair and its therapeutic exploita..:

, In: DNA Repair in Cancer Therapy,
D'Arcangelo, M. ; Drew, Y. ; Plummer, R. - p. 115-134 , 2016
Link: https://doi.org/10.1016/..
 
?
5

2746 A Phase 2 open-label, multicenter study of single-agen..:

Shapira-Frommer, R. ; Oza, A. ; Domchek, S.M....
European Journal of Cancer.  51 (2015)  - p. S545 , 2015
Link: https://doi.org/10.1016/..
 
?
6

Academic Opportunities within Clinical Oncology Training:

Goranov, B.B. ; Drew, Y. ; Graham, J....
Clinical Oncology.  25 (2013)  7 - p. 446 , 2013
Link: https://doi.org/10.1016/..
 
?
7

245 INVITED PARP inhibitors in cancer treatment:

Calvert, H. ; Plummer, E.R. ; Curtin, N.J...
European Journal of Cancer Supplements.  6 (2008)  12 - p. 80 , 2008
Link: https://doi.org/10.1016/..
 
?
8

Reactions of reduced cyclophanes: Electrophilic bromination..:

Robinson, Randall E. ; Myers, Drew Y.
Tetrahedron Letters.  40 (1999)  6 - p. 1099-1100 , 1999
Link: https://doi.org/10.1016/..
 
?
9

Olaparib plus Durvalumab, with or without Bevacizumab, as T..:

Drew, Y ; Kim, J-W ; Penson, RT...
730052.  , 2024
Link: https://repository.icr.a..
 
?
10

Prevalence of mutations in common tumour types in Northern ..:

Rae, S ; Plummer, E ; Fitzgerald, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645649/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
11

Real-World Delivery of Rucaparib to Patients with Ovarian C..:

Drew, Y ; Kristeleit, RS ; Oaknin, A...
https://discovery.ucl.ac.uk/id/eprint/10085804/1/Kristeleit_Real-World%20Delivery%20of%20Rucaparib%20to%20Patients%20with%20Ovarian%20Cancer_VoR.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
12

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibi..:

Yap, TA ; Kristeleit, R ; Michalarea, V...
Cancer discovery, 2020, 10 (10), pp. 1528 - 1543.  , 2020
Link: https://repository.icr.a..
 
?
13

Tisotumab Vedotin in Previously Treated Recurrent or Metast..:

Hong, DS ; Concin, N ; Vergote, I...
https://discovery.ucl.ac.uk/id/eprint/10091372/3/Forster_Tisotumab%20Vedotin%20in%20Previously%20Treated%20Recurrent%20or%20Metastatic%20Cervical%20Cancer_AAM.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
14

Antitumor activity of the poly(ADP-ribose) polymerase inhib..:

Kristeleit, RS ; Oaknin, A ; Ray-Coquard, I...
https://discovery.ucl.ac.uk/id/eprint/10086074/1/1396.full.pdf.  , 2019
Link: https://discovery.ucl.ac..
 
?
15

Antitumor activity of the poly(ADP-ribose) polymerase inhib..:

Kristeleit, RS ; Oaknin, A ; Ray-Coquard, I...
International Journal of Gynecologic Cancer.  , 2019
Link: http://hdl.handle.net/10..
 
1-15